China’s population continued to decline last year—though births edged up for the first time in eight years—falling for a ...

I’m on a journey to cook more and use Uber Eats a little less,” this renter says — and now she has a kitchen where that can ...

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Hutchmed (HCM) announces that the supplemental new drug application for Orpathys has been granted approval by the China National Medical Products Administration, or NMPA, for the treatment of adult ...

has been granted approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) ...

A look at the shareholders of HUTCHMED (China) Limited (LON:HCM) can tell us which group is most powerful. The group holding the most number of shares in the company, around 39% to be precise, is ...

“The small fishermen of Zambales, especially those driven by China in the West Philippine Sea, fear the increased influx of commercial fishing vessels in our traditional fisheries,” Marabe ...

China National Medical Products Administration ... combination for patients with locally advanced or metastatic non-small cell lung cancer. This is specifically indicated for individuals positive ...

These environmental challenges are more significant threats to U.S. commerce than Chinese influence. Sustained access to the canal will depend on addressing climate change impacts. NYT News Service ...

SHPL is a commercially focused joint venture that primarily sells cardiovascular prescription drugs in China. China-based ... mutation-positive non-small cell lung cancer (NSCLC).